Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose temozolomide plus metformin vs temozolomide plus placebo in recurrent or refractory glioblastoma
KCT0002632Phase 2Completed
- Sponsor
- Shinpoong Pharma
- Start
- Nov 2016
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide, metformin in glioblastoma (GBM), sponsored by Shinpoong Pharma. Started Nov 2016; status: completed.
02
Drugs
temozolomidemetformin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on KCT0002632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002632.